Redcare Pharmacy NV (RDC.DE)
EUR 139.9
(-3.38%)
EUR 139.9
(-3.38%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -12.04 Million EUR | 84.49% |
| 2022 | -77.64 Million EUR | -4.67% |
| 2021 | -74.18 Million EUR | -342.34% |
| 2020 | -16.77 Million EUR | 53.76% |
| 2019 | -36.27 Million EUR | -7.92% |
| 2018 | -33.6 Million EUR | -57.36% |
| 2017 | -21.35 Million EUR | -15.79% |
| 2016 | -18.44 Million EUR | -74.87% |
| 2015 | -10.54 Million EUR | -109.49% |
| 2014 | -5.03 Million EUR | -77.85% |
| 2013 | -2.83 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -7.8 Million EUR | -39.85% |
| 2024 Q2 | -4.26 Million EUR | 45.34% |
| 2023 Q1 | -10.22 Million EUR | -4.65% |
| 2023 Q3 | 8.31 Million EUR | 282.55% |
| 2023 Q2 | -4.55 Million EUR | 55.42% |
| 2023 Q4 | -5.58 Million EUR | -167.09% |
| 2023 FY | -12.04 Million EUR | 84.49% |
| 2022 Q3 | -20.12 Million EUR | 18.95% |
| 2022 Q4 | -9.76 Million EUR | 51.45% |
| 2022 FY | -77.64 Million EUR | -4.67% |
| 2022 Q1 | -22.93 Million EUR | 46.02% |
| 2022 Q2 | -24.82 Million EUR | -8.25% |
| 2021 Q1 | -5.79 Million EUR | 20.83% |
| 2021 Q2 | -11.17 Million EUR | -92.95% |
| 2021 Q3 | -14.73 Million EUR | -31.93% |
| 2021 FY | -74.18 Million EUR | -342.34% |
| 2021 Q4 | -42.48 Million EUR | -188.24% |
| 2020 Q3 | -4.33 Million EUR | -2577.78% |
| 2020 FY | -16.77 Million EUR | 53.76% |
| 2020 Q4 | -7.31 Million EUR | -68.58% |
| 2020 Q2 | -162 Thousand EUR | 96.73% |
| 2020 Q1 | -4.95 Million EUR | 15.42% |
| 2019 Q2 | -6.6 Million EUR | 55.12% |
| 2019 FY | -36.27 Million EUR | -7.92% |
| 2019 Q1 | -14.72 Million EUR | -37.81% |
| 2019 Q4 | -5.86 Million EUR | 35.44% |
| 2019 Q3 | -9.08 Million EUR | -37.43% |
| 2018 Q4 | -10.68 Million EUR | -33.56% |
| 2018 FY | -33.6 Million EUR | -57.36% |
| 2018 Q1 | -8.1 Million EUR | 7.57% |
| 2018 Q2 | -6.82 Million EUR | 15.85% |
| 2018 Q3 | -7.99 Million EUR | -17.24% |
| 2017 Q1 | -5.43 Million EUR | 42.24% |
| 2017 Q2 | -2.68 Million EUR | 50.63% |
| 2017 Q4 | -8.77 Million EUR | -96.53% |
| 2017 Q3 | -4.46 Million EUR | -66.22% |
| 2017 FY | -21.35 Million EUR | -15.79% |
| 2016 Q4 | -9.41 Million EUR | -235.69% |
| 2016 Q3 | -2.8 Million EUR | -8.05% |
| 2016 Q2 | -2.59 Million EUR | 28.45% |
| 2016 Q1 | -3.62 Million EUR | 6.37% |
| 2016 FY | -18.44 Million EUR | -74.87% |
| 2015 Q1 | -1.96 Million EUR | 0.0% |
| 2015 FY | -10.54 Million EUR | -109.49% |
| 2015 Q2 | -1.96 Million EUR | 0.0% |
| 2015 Q4 | -3.87 Million EUR | -41.32% |
| 2015 Q3 | -2.74 Million EUR | -39.51% |
| 2014 FY | -5.03 Million EUR | -77.85% |
| 2013 FY | -2.83 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Newron Pharmaceuticals S.p.A. | -16.22 Million EUR | 25.783% |